NervGen Pharma Corp. (NGEN)
1.78
+0.02
(+1.14%)
USD |
NASDAQ |
Oct 02, 16:00
1.82
+0.04
(+2.25%)
After-Hours: 20:00
NervGen Pharma Max Drawdown (5Y) : 73.37% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 73.37% |
| August 31, 2026 | 73.37% |
| July 31, 2026 | 73.37% |
| June 30, 2026 | 71.02% |
| May 31, 2026 | 65.33% |
| April 30, 2026 | 57.76% |
| March 31, 2026 | 57.76% |
| February 28, 2026 | 57.76% |
| January 31, 2026 | 57.76% |
| December 31, 2025 | 57.76% |
| November 30, 2025 | 57.76% |
| October 31, 2025 | 57.76% |
| September 30, 2025 | 57.76% |
| August 31, 2025 | 61.14% |
| July 31, 2025 | 61.14% |
| June 30, 2025 | 61.14% |
| May 31, 2025 | 61.14% |
| April 30, 2025 | 61.14% |
| March 31, 2025 | 68.31% |
| February 28, 2025 | 72.86% |
| January 31, 2025 | 72.86% |
| December 31, 2024 | 72.86% |
| November 30, 2024 | 72.86% |
| October 31, 2024 | 72.86% |
| September 30, 2024 | 72.86% |
| Date | Value |
|---|---|
| August 31, 2024 | 72.86% |
| July 31, 2024 | 72.86% |
| June 30, 2024 | 72.86% |
| May 31, 2024 | 72.86% |
| April 30, 2024 | 72.86% |
| March 31, 2024 | 72.86% |
| February 29, 2024 | 72.86% |
| January 31, 2024 | 72.86% |
| December 31, 2023 | 72.86% |
| November 30, 2023 | 72.86% |
| October 31, 2023 | 72.86% |
| September 30, 2023 | 72.86% |
| August 31, 2023 | 72.86% |
| July 31, 2023 | 72.86% |
| June 30, 2023 | 72.86% |
| May 31, 2023 | 72.86% |
| April 30, 2023 | 72.86% |
| March 31, 2023 | 72.86% |
| February 28, 2023 | 72.86% |
| January 31, 2023 | 72.86% |
| December 31, 2022 | 72.86% |
| November 30, 2022 | 72.86% |
| October 31, 2022 | 72.86% |
| September 30, 2022 | 72.86% |
| August 31, 2022 | 72.86% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| InMed Pharmaceuticals, Inc. | 99.97% |
| Milestone Pharmaceuticals, Inc. | 95.25% |
| Clearmind Medicine, Inc. | -- |
| Lexaria Bioscience Corp. | 99.02% |
| Target Group, Inc. (Canada) | 99.99% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -11.71 |
| Beta (5Y) | 0.8241 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 73.15% |
| Historical Sharpe Ratio (5Y) | -0.0474 |
| Historical Sortino (5Y) | -0.0989 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 27.30% |